PD-L1 expression
PD-L1 expression
|
Triple Negative Breast Cancer
Triple Negative Breast Cancer
|
pembrolizumab
Merck (MSD) Press Release - 1 week
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
PD1 inhibitor + Angiogenesis inhibitor
Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks
|
PD-L1 expression
PD-L1 expression
|
Triple Negative Breast Cancer
Triple Negative Breast Cancer
|
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
|
PD-L1 expression
PD-L1 expression
|
Urothelial Cancer
Urothelial Cancer
|
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
|
PD-L1 expression
PD-L1 expression
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
|
PD-L1 expression
PD-L1 expression
|
|
|
PD-L1 expression
PD-L1 expression
|
Cervical Cancer
Cervical Cancer
|
|
PD-L1 expression
PD-L1 expression
|
Urothelial Cancer
Urothelial Cancer
|
|
PD-L1 expression
PD-L1 expression
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
|
PD-L1 expression
PD-L1 expression
|
Esophageal Cancer
Esophageal Cancer
|
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
atezolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
ADX-2191
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
cetuximab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
5-fluorouracil
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Bladder Cancer
Bladder Cancer
|
atezolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Bladder Cancer
Bladder Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Head and Neck Cancer
Head and Neck Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Lung Non-Small Cell Squamous Cancer
Lung Non-Small Cell Squamous Cancer
|
nivolumab + ipilimumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab + ipilimumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Lung Non-Small Cell Squamous Cancer
Lung Non-Small Cell Squamous Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Vulvar Cancer
Vulvar Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
nivolumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
|
pembrolizumab + axitinib
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Small Cell Lung Cancer
Small Cell Lung Cancer
|
atezolizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
|
pembrolizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Gastric Cancer
Gastric Cancer
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
CS1001
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Gastric Cancer
Gastric Cancer
|
Immunotherapy
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Immunotherapy
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Ovarian Cancer
Ovarian Cancer
|
bevacizumab + atezolizumab
Resistant: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
tislelizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
|
nivolumab + cabozantinib tablet
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Urothelial Cancer
Urothelial Cancer
|
avelumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Urothelial Cancer
Urothelial Cancer
|
durvalumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Urothelial Cancer
Urothelial Cancer
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
|
nivolumab + ipilimumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
durvalumab + CP-675206
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
|
pembrolizumab + axitinib
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
|
bevacizumab + atezolizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
|
nivolumab + ipilimumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Bladder Cancer
Bladder Cancer
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Ovarian Cancer
Ovarian Cancer
|
atezolizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Ovarian Cancer
Ovarian Cancer
|
CPB
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
nivolumab + ipilimumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Cutaneous Melanoma
Cutaneous Melanoma
|
pembrolizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
tislelizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Non Small Cell Lung Cancer
NSCLC
|
nivolumab + bevacizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab + ipilimumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
|
atezolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
durvalumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Gastric Cancer
Gastric Cancer
|
nivolumab + ipilimumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Anal Carcinoma
Anal Carcinoma
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Prostate Cancer
Prostate Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Squamous Cell Skin Cancer
Squamous Cell Skin Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Prostate Cancer
Prostate Cancer
|
durvalumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Bladder Cancer
Bladder Cancer
|
durvalumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Biliary Tract Cancer
Biliary Tract Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Ovarian Cancer
Ovarian Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
|
durvalumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Kaposi Sarcoma
Kaposi Sarcoma
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Biliary Tract Cancer
Biliary Tract Cancer
|
nivolumab + ipilimumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Triple Negative Breast Cancer
Triple Negative Breast Cancer
|
durvalumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
|
atezolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
|
durvalumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Gastric Cancer
Gastric Cancer
|
durvalumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Prostate Cancer
Prostate Cancer
|
nivolumab + ipilimumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
|
atezolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Pancreatic Cancer
Pancreatic Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Small Cell Lung Cancer
Small Cell Lung Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
|
pembrolizumab
Sensitive: C1 - Off-label
|
